title: Effect of low-dose aspirin for skin rash associated with erlotinib therapy in patients with lung cancer.
authors.forename: Shigenori
authors.initials: S
authors.lastname: Kanazawa
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Yamaguchi
authors.forename: Yoshimi
authors.initials: Y
authors.lastname: Kinoshita
authors.forename: Kyouko
authors.initials: K
authors.lastname: Siomi
authors.forename: Masako
authors.initials: M
authors.lastname: Tujimoto
authors.forename: Kayoko
authors.initials: K
authors.lastname: Hanayama
authors.forename: Shinji
authors.initials: S
authors.lastname: Sasada
authors.forename: Tomonori
authors.initials: T
authors.lastname: Hirashima
authors.forename: Fumio
authors.initials: F
authors.lastname: Imamura
authors.forename: Shosaku
authors.initials: S
authors.lastname: Nomura
mesh_terms: D000368:Aged; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D000069347:Erlotinib Hydrochloride; D005076:Exanthema / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D015539:Platelet Activation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use; D013929:Thromboxane B2 / Q000097:blood; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D013929:Thromboxane B2; D000069347:Erlotinib Hydrochloride; D001241:Aspirin